PHILADELPHIA, Jan. 29 (HSMN NewsFeed) — GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral t…
Biopharmaceuticals, Oncology, FDA
GlaxoSmithKline, TYKERB, lapatinib, metastatic breast cancer, breast cancer

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “GSK’s TYKERB(R) Receives Accelerated Approval for First-Line Combination Treatment of Metastatic Breast Cancer”
Leave a Comment